AQR Capital Management
ZYME icon

AQR Capital Management’s Zymeworks ZYME Stock Holding History

AQR Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Sell
90,669
-406
-0.4% -$9.61K ﹤0.01% 2262
2025
Q4 		$2.4M Sell
91,075
-61,557
-40% -$1.34M ﹤0.01% 2027
2025
Q3 		$2.61M Sell
152,632
-13,511
-8% -$193K ﹤0.01% 1819
2025
Q2 		$2.09M Buy
166,143
+117,658
+243% +$1.4M ﹤0.01% 1745
2025
Q1 		$577K Buy
48,485
+22,411
+86% +$306K ﹤0.01% 2343
2024
Q4 		$382K Buy
26,074
+1,212
+5% +$16.9K ﹤0.01% 2385
2024
Q3 		$312K Sell
24,862
-69,410
-74% -$756K ﹤0.01% 2377
2024
Q2 		$802K Sell
94,272
-395,230
-81% -$3.52M ﹤0.01% 1853
2024
Q1 		$5.15M Sell
489,502
-196,688
-29% -$2.18M 0.01% 973
2023
Q4 		$7.13M Sell
686,190
-113,489
-14% -$904K 0.01% 820
2023
Q3 		$5.07M Buy
799,679
+330,213
+70% +$2.44M 0.01% 924
2023
Q2 		$4.06M Buy
+469,466
New +$4.2M 0.01% 977
2022
Q2 		– Sell
-12,445
Closed -$82K – 2315
2022
Q1 		$82K Buy
+12,445
New +$111K ﹤0.01% 2151

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management's ZYME Position: Q1 2026 in Review

AQR Capital Management reduced its Zymeworks (ZYME) stake by 0.45% in Q1 2026, selling an estimated $9.61K and leaving 90,669 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

AQR Capital Management first reported a position in ZYME in Q1 2022 and has held it in 13 quarters since. The position peaked at $7.13M in Q4 2023. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • AQR Capital Management held 90,669 shares of Zymeworks worth $2.27M as of Q1 2026.
  • AQR Capital Management sold 406 Zymeworks shares in Q1 2026, an estimated $9.61K.
  • Zymeworks made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2262 holding.
  • AQR Capital Management first reported a position in Zymeworks in Q1 2022 and has held it in 13 quarters since.
  • AQR Capital Management's Zymeworks position peaked at $7.13M in Q4 2023.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.